What is the appropriate presumptive treatment regimen for an unspecified sexually transmitted infection?

Presumptive STI Treatment

For presumptive treatment of an unspecified sexually transmitted infection, administer ceftriaxone 250 mg IM PLUS azithromycin 1 g orally as a single dose, which provides dual coverage for gonorrhea and chlamydia—the two most common bacterial STIs. 1

Treatment Rationale

This dual therapy approach is the standard presumptive regimen because:

• Chlamydia and gonorrhea frequently coexist (coinfection rates are substantial)
• Both infections are often asymptomatic, making clinical differentiation impossible
• Compliance with follow-up is notoriously poor in STI populations, making same-day treatment critical 1
• Complications from untreated infections (PID, epididymitis, infertility) justify empiric coverage

Clinical Algorithm

When to Treat Presumptively:

1. Symptomatic patients with urethritis, cervicitis, or pelvic inflammatory disease where testing results won't be available immediately
2. High-risk exposures (known infected partner, sexual assault)
3. Patients unlikely to return for follow-up 2, 1
4. Settings with high local prevalence (>5% gonorrhea prevalence warrants dual coverage) 2

Add Metronidazole 2 g orally if:

• Vaginal discharge suggests trichomoniasis or bacterial vaginosis
• Sexual assault cases 1
• Symptoms of vaginal malodor or irritation

Special Populations

Pregnancy:

• Use ceftriaxone 250 mg IM PLUS azithromycin 1 g orally
• Avoid doxycycline and quinolones (teratogenic) 3, 4
• Erythromycin is an alternative to azithromycin if needed 3

Penicillin/Cephalosporin Allergy:

• This is problematic as spectinomycin (the traditional alternative) is no longer widely available
• Consider desensitization for true allergy in high-risk cases
• Azithromycin 2 g as monotherapy is suboptimal but may be necessary 4

Critical Pitfalls to Avoid

Do not use quinolones (ciprofloxacin, levofloxacin) for gonorrhea due to widespread resistance, despite their appearance in older guidelines [5-5]. The 2010 Taiwan guidelines showing quinolone options are outdated for current practice.

Do not use azithromycin monotherapy for gonorrhea due to emerging resistance—always pair with ceftriaxone 6

Do not skip treatment while awaiting test results in high-risk patients—approximately 46% of patients tested for gonorrhea/chlamydia receive empiric treatment, and this prevents complications 7, 8

Partner Management

• Treat all sexual partners from the past 60 days with the same regimen 4
• Expedited partner therapy (providing medication for partners without examination) is acceptable in many jurisdictions
• Instruct patients to abstain from sex for 7 days after single-dose therapy or until completion of multi-day regimens 9, 2

Testing Considerations

While treating presumptively, always obtain diagnostic testing (NAAT for gonorrhea/chlamydia) before treatment when possible to:

• Confirm diagnosis
• Guide partner notification
• Monitor local resistance patterns
• Document treatment need for medicolegal purposes

The evidence shows that only 17.6% of patients with lower genitourinary symptoms receive appropriate STI testing 10, representing a major gap in care. Even when treating presumptively, collect specimens first.

Follow-Up

Test-of-cure is NOT routinely needed for uncomplicated gonorrhea/chlamydia treated with recommended regimens 4

DO perform test-of-cure for:

• Pharyngeal gonorrhea (all cases) 6
• Rectal chlamydia treated with azithromycin 6
• Pregnant patients
• Persistent symptoms after treatment